UBS O'Connor’s AstraZeneca AZN Stock Holding History

UBS O'Connor’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,500	Closed	-$10.3K	–	510
2024 Q2	$10.3K	Buy	+7,500	New	+$1.13M	﹤0.01%	502

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS O'Connor's AZN Position: Q3 2025 in Review

UBS O'Connor sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 21,499 shares — an estimated $3M sold.

UBS O'Connor first reported a position in AZN in Q2 2014 and held it in 13 quarters. The position peaked at $6.57M in Q2 2014. 1,288 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

UBS O'Connor reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 21,499 AstraZeneca shares in Q3 2025, an estimated $3M.
UBS O'Connor first reported a position in AstraZeneca in Q2 2014 and held it in 13 quarters.
UBS O'Connor's AstraZeneca position peaked at $6.57M in Q2 2014.
1,288 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.